With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Peer-Reviewed Data Show Durable HbA1c Reduction, Significant Weight Loss, and a Favorable Safety Profile Through 48 Weeks Following a Single Endoscopic Procedure for Type 2 Diabetes ...

Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early ...

Each of these companies could benefit from this high-growth market over time.

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

One pill for obesity is already on the market, and more are on the way. But the injected drugs have key advantages.

"It’s crazy how differently everyone reacts. Not just weight loss, but hair, mood, and even organ health." View Entire Post › ...

Three new studies reveal surprising insights on GLP-1 weight loss drugs, opioid treatment in pregnancy, and the real science ...